^
Association details:
| Biomarker: | CRLF2 rearrangement |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Drug Class: | T-lymphocyte cell therapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Excerpt:
...CRLF2 rearrangement with confirmed JAK1 or JAK2 mutation (JAK+) 2....
Trial ID:
Source:
Title:
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
Excerpt:
...- Cytokine receptor-like factor 2 (CRLF2) rearranged (JAK2 mutant or wild-type)...
Trial ID:
Less C2 evidence
Source:
Title:
BIMODAL TARGETING OF CYTOKINE RECEPTOR-LIKE FACTOR 2 (CRLF2) WITH JAK INHIBITION AND CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY IN DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA
Published date:
05/12/2022
Excerpt:
In the present studies, we investigated the effects of TSLPRCART +/- ruxolitinib co-treatment in vitro and in vivo against CRLF2-R human ALL cell lines and childhood DS-ALL patient-derived xenograft (PDX) models (n=4).... As expected, treatment of CRLF2-R DS-ALL PDX models with TSLPRCART potently inhibited in vivo leukemia proliferation and induced long-term ‘cure’ of animals. However, simultaneous co-treatment of engrafted mice with ruxolitinib and TSLPRCART led to markedly diminished in vivo T cell proliferation and persistence, blunted cytokine production, and facilitated eventual leukemia relapse....TSLPRCART is a promising cellular immunotherapeutic approach for DS-ALL and for BCR-ABL1-like ALL given shared features of CRLF2 rearrangement and cell surface protein overexpression.
